[go: up one dir, main page]

PE20060301A1 - DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2 - Google Patents

DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2

Info

Publication number
PE20060301A1
PE20060301A1 PE2005000686A PE2005000686A PE20060301A1 PE 20060301 A1 PE20060301 A1 PE 20060301A1 PE 2005000686 A PE2005000686 A PE 2005000686A PE 2005000686 A PE2005000686 A PE 2005000686A PE 20060301 A1 PE20060301 A1 PE 20060301A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
pyridin
benzyl
halogen
Prior art date
Application number
PE2005000686A
Other languages
English (en)
Inventor
Kamlesh Jagdis Bala
Catherine Leblanc
Katharine Louise Turner
Brian Cox
Lyndon Nigel Brown
Simon James Watson
David Andrew Sandham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413619A external-priority patent/GB0413619D0/en
Priority claimed from GB0507693A external-priority patent/GB0507693D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20060301A1 publication Critical patent/PE20060301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE LA FORMULA I, DONDE Q ES UN ENLACE, ALQUILENO C1-C10 SUSTITUIDO O NO POR HALOGENO; R1 Y R2 SON CADA UNO H, HALOGENO, ALQUILO C1-C8, ENTRE OTROS; R3 ES H, ALQUILO C1-C8, CARBOCICLO C3-C15, HALOALQUILO C1-C8, ENTRE OTROS; R4 Y R5 SON CADA UNO HALOGENO, ALQUILO C1-C8, HALOALQUILO C1-C8, ENTRE OTROS; R6 ES H, ALQUILO C1-C8; W ES CARBOCICLICO AROMATICO DE C6-C15, HETEROCICLICO DE 4-10 MIEMBROS CON AL MENOS UN HETEROATOMO SELECCIONADO DE N, O, S; X ES -SO2-, -CH2-, -CON- (ALQUILO C1-C8), ENTRE OTROS; m Y n SON CADA UNO 0-3; p ES 1. SON COMPUESTOS PREFERIDOS: ACIDO (1-BENCIL-2-METIL-1H-PIRROLO-[2,3-b]-PIRIDIN-3-IL)-ACETICO; [1-(3,4-DICLORO-BENCIL)-2-METIL-1H-PIRROLO-[2,3-b]-PIRIDIN-3-IL)-ACETICO; ACIDO [2-METIL-1-(2-METIL-BENCIL)-1H-PIRROLO-[2,3-b]-PIRIDIN-3-IL]-ACETICO. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DE LA CRTh2 RECEPTORA QUIMIOATRAYENTE ACOPLADA CON PROTEINA-G SIENDO UTILES EN EL TRATAMIENTO DE CONDICIONES ALERGICAS, INFLAMATORIAS TALES COMO ASMA, PSORIASIS, CONJUNTIVITIS, ANEMIA APLASICA, ENTRE OTROS
PE2005000686A 2004-06-17 2005-06-15 DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2 PE20060301A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0413619A GB0413619D0 (en) 2004-06-17 2004-06-17 Organic compounds
GB0507693A GB0507693D0 (en) 2005-04-15 2005-04-15 Organic compounds

Publications (1)

Publication Number Publication Date
PE20060301A1 true PE20060301A1 (es) 2006-05-18

Family

ID=35510318

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000686A PE20060301A1 (es) 2004-06-17 2005-06-15 DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2

Country Status (28)

Country Link
US (5) US7666878B2 (es)
EP (1) EP1761529B3 (es)
JP (1) JP4886680B2 (es)
KR (1) KR101183330B1 (es)
AR (1) AR049443A1 (es)
AT (1) ATE378338T1 (es)
AU (1) AU2005254681B2 (es)
BR (1) BRPI0512060B8 (es)
CA (1) CA2569125C (es)
CY (1) CY1107851T1 (es)
DE (1) DE602005003365T3 (es)
DK (1) DK1761529T3 (es)
EC (1) ECSP067077A (es)
ES (1) ES2294717T7 (es)
HR (1) HRP20080022T4 (es)
IL (1) IL179604A (es)
MA (1) MA28666B1 (es)
MX (1) MXPA06014694A (es)
MY (1) MY144903A (es)
NO (1) NO338319B1 (es)
NZ (1) NZ551439A (es)
PE (1) PE20060301A1 (es)
PL (1) PL1761529T6 (es)
PT (1) PT1761529E (es)
RS (1) RS50552B (es)
RU (1) RU2379309C2 (es)
TW (1) TWI352702B (es)
WO (1) WO2005123731A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
PT1986633E (pt) 2006-02-10 2014-11-05 Summit Corp Plc Tratamento da distrofia muscular de duchenne
GB0611695D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
BRPI0715179A2 (pt) 2006-08-07 2013-06-11 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
CA2685540C (en) * 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
EP2268281A4 (en) 2008-02-15 2012-05-02 Abbott Lab THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS
WO2010019905A1 (en) * 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
JP5524209B2 (ja) 2008-08-15 2014-06-18 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼのピロール阻害剤
ES2572615T3 (es) 2008-08-15 2016-06-01 Nivalis Therapeutics, Inc. Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos
SG183835A1 (en) 2010-03-22 2012-10-30 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
BR112013015397A2 (pt) 2010-12-23 2016-09-20 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
MY165623A (en) 2011-04-14 2018-04-18 Idorsia Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AR089653A1 (es) 2011-10-25 2014-09-10 Shionogi & Co Derivados heterociclicos que tienen actividad antagonista del receptor de pgd2
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
TWI649321B (zh) 2014-03-17 2019-02-01 瑞士商愛杜西亞製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途
JP6484644B2 (ja) 2014-03-18 2019-03-13 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
US10689383B2 (en) 2014-08-04 2020-06-23 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
CA2992987A1 (en) 2015-07-23 2017-01-26 Merck Sharp & Dohme Corp. Genetic markers associated with response to crth2 receptor antagonists
CN108026093B (zh) 2015-09-15 2021-11-16 爱杜西亚药品有限公司 结晶形式
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
KR20180058724A (ko) * 2015-09-29 2018-06-01 노파르티스 아게 1-(4-메탄술포닐-2-트리플루오로메틸-벤질)-2-메틸-1H-피롤로 [2,3-b]피리딘-3-일-아세트산의 제조 방법
WO2017210261A1 (en) * 2016-05-31 2017-12-07 Concert Pharmaceuticals, Inc. Deuterated fevipiprant
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CN106188040B (zh) * 2016-06-28 2018-03-23 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法
US11524958B2 (en) 2016-07-21 2022-12-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound as CRTH2 inhibitor
US20180280394A1 (en) 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease
WO2018176343A1 (en) 2017-03-30 2018-10-04 Xw Laboratories Inc. Bicyclic heteroaryl derivatives and preparation and uses thereof
JOP20190223A1 (ar) * 2017-04-01 2019-09-26 Novartis Ag عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
PE20200743A1 (es) 2017-06-30 2020-07-24 Univ California Composiciones y metodos para modular el crecimiento del cabello
WO2019011337A1 (zh) * 2017-07-14 2019-01-17 苏州科睿思制药有限公司 Qaw-039的晶型及其制备方法和用途
WO2019130166A1 (en) * 2017-12-26 2019-07-04 Mankind Pharma Ltd. Preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoro methyl)phenyl]methyl] pyrrolo[2,3-b]pyridin-3-yl]acetic acid
JP7296970B2 (ja) 2018-01-19 2023-06-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド インドール誘導体の結晶形とその調製方法および使用
CN110467612B (zh) * 2018-05-09 2020-09-25 新发药业有限公司 一种前列腺素d2受体抑制剂化合物的简便制备方法
CN112004802B (zh) 2018-09-30 2021-12-28 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
HUE065889T2 (hu) 2019-01-15 2024-06-28 Gilead Sciences Inc Izoxazol vegyület mint FXR agonista és az azt tartalmazó gyógyszerészeti készítmények
KR20240160667A (ko) 2019-02-19 2024-11-11 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
EP4077262B1 (en) 2019-12-20 2024-07-24 XWPharma Ltd. Methods of synthesizing 4-valyloxybutyric acid
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
PE20230240A1 (es) 2019-12-20 2023-02-07 Nuevolution As Compuestos activos frente a receptores nucleares
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
JP7713953B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3183185A1 (en) 2020-06-18 2021-12-23 Jia-Ning Xiang Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN117618393A (zh) 2020-06-18 2024-03-01 凯瑞康宁生物工程（武汉）有限公司 水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
TW202228665A (zh) 2020-10-05 2022-08-01 凱瑞康寧生技股份有限公司 γ－羥基丁酸衍生物之修飾釋放組合物
EP4588471A3 (en) 2021-03-19 2025-09-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320268A (en) * 1964-08-14 1967-05-16 Merck & Co Inc 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives
US5212195A (en) 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
AU687196B2 (en) * 1994-06-16 1998-02-19 Pfizer Inc. Pyrazolo and pyrrolopyridines
TWI262920B (en) 2000-10-27 2006-10-01 Elbion Ag New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
WO2003022813A1 (en) * 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Indole derivatives, process for producing the same and drugs containing the same as the active ingredient
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1505061A4 (en) 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2008502638A (ja) 2008-01-31
CY1107851T1 (el) 2013-06-19
US20080114022A1 (en) 2008-05-15
ES2294717T7 (es) 2012-06-14
BRPI0512060A (pt) 2008-02-06
US8791256B2 (en) 2014-07-29
KR101183330B1 (ko) 2012-09-17
RU2379309C2 (ru) 2010-01-20
WO2005123731A2 (en) 2005-12-29
US20140309254A1 (en) 2014-10-16
US9169251B2 (en) 2015-10-27
US20130267518A1 (en) 2013-10-10
MXPA06014694A (es) 2007-02-12
JP4886680B2 (ja) 2012-02-29
US7666878B2 (en) 2010-02-23
WO2005123731A3 (en) 2006-05-04
RU2007101277A (ru) 2008-07-27
DE602005003365T2 (de) 2008-09-11
PL1761529T6 (pl) 2011-11-30
BRPI0512060B8 (pt) 2021-05-25
KR20070032694A (ko) 2007-03-22
EP1761529B3 (en) 2011-06-15
TWI352702B (en) 2011-11-21
ATE378338T1 (de) 2007-11-15
NZ551439A (en) 2009-09-25
CA2569125A1 (en) 2005-12-29
BRPI0512060B1 (pt) 2018-08-07
HK1103730A1 (en) 2007-12-28
EP1761529B1 (en) 2007-11-14
CA2569125C (en) 2013-01-08
MY144903A (en) 2011-11-30
HRP20080022T3 (en) 2008-02-29
NO338319B1 (no) 2016-08-08
AR049443A1 (es) 2006-08-02
PL1761529T3 (pl) 2008-04-30
EP1761529A2 (en) 2007-03-14
US8470848B2 (en) 2013-06-25
RS50552B (sr) 2010-05-07
ES2294717T3 (es) 2008-04-01
MA28666B1 (fr) 2007-06-01
NO20070323L (no) 2007-03-12
DK1761529T3 (da) 2008-03-25
ECSP067077A (es) 2007-01-26
TW200617009A (en) 2006-06-01
AU2005254681B2 (en) 2009-01-29
IL179604A0 (en) 2007-05-15
US8455645B2 (en) 2013-06-04
US20100210610A1 (en) 2010-08-19
HRP20080022T4 (hr) 2011-10-31
AU2005254681A1 (en) 2005-12-29
DE602005003365T3 (de) 2012-08-30
PT1761529E (pt) 2008-02-11
US20100204225A1 (en) 2010-08-12
DE602005003365D1 (de) 2011-01-05
IL179604A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
PE20060301A1 (es) DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2
PE20080839A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20091884A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparacion, asi como su uso como medicamento
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
AR075084A1 (es) Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
WO2005060665A8 (en) 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
PE20081164A1 (es) Nuevos compuestos 521
DE602005014086D1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
PE20040120A1 (es) Derivados de quinolina como antagonistas de npy
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
PE20080889A1 (es) Aminometil-4-imidazoles
TN2009000112A1 (fr) Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques
PE20061088A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a
PE20060878A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
WO2008078762A1 (ja) ウレア構造を有する新規ｎ－(２－アミノフェニル)ベンズアミド誘導体
AR071925A1 (es) Malonamidas como antagonistas de orexina
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
PE20120810A1 (es) Compuestos derivados de 5-ciano-2-(feniltio)bencensulfonamida como antagonistas de ccr3
EP2007729A1 (en) Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
ATE529181T1 (de) Neuartiges dispersionsmittel und zusammensetzungen daraus
PE20081683A1 (es) Nuevos derivados de sulfonamida
DE602006010540D1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor

Legal Events

Date Code Title Description
FG Grant, registration